Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder

Psychopharmacology

Volumn 213, Issue 4, 2011, Pages 657-667

  Popovic, Dina ^a,b   Reinares, Maria ^a   Amann, Benedikt ^c   Salamero, Manel ^a   Vieta, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF PISA   (Italy)

^c Benito Menni Complex Assistencial en Salut Mental   (Spain)

Author keywords

Bipolar disorder; Maintenance treatment; NNT; Treatment efficacy

Indexed keywords

ARIPIPRAZOLE; LAMOTRIGINE; LITHIUM; OLANZAPINE; OXCARBAZEPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ADD ON THERAPY; BIPOLAR DISORDER; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; HUMAN; MAINTENANCE THERAPY; MANIA; MOOD DISORDER; PRIORITY JOURNAL; RELAPSE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952488779     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-2056-8     Document Type: Review

References (33)

1. Altman DG (1998) Confidence intervals for the number needed to treat. BMJ 317:1309-1312
2. Altman DG, Deeks JJ (2002) Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol 2:3
3. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG Jr, Chou JC, Keck PE Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 57:481-489 (Pubitemid 30257262)
4. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J, Lamictal 606 Study Group (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60:392-400 (Pubitemid 36403000)
5. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M (2010) Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 71:130-137
6. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET, Lamictal 614 Study Group (2000) A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 61:841-850
7. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J, Lamictal 605 Study Group (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64:1013-1024
8. Calabrese JR, Vieta E, El-Mallakh R, Findling RL, Youngstrom EA, Elhaj O, Gajwani P, Pies R (2004) Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 56:957-963 (Pubitemid 39643054)
9. Calabrese JR, Goldberg JF, Ketter TA, Suppes T, Frye M, White R, DeVeaugh-Geiss A, Thompson TR (2006) Recurrence in bipolar I disorder: a post hoc analysis excluding relapses in two double-blind maintenance studies. Biol Psychiatry 59:1061-1064 (Pubitemid 43849661)
10. Citrome L (2008) Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 117:412-419
11. Colom F, Vieta E, Daban C, Pacchiarotti I, Sánchez-Moreno J (2006) Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 93:13-17 (Pubitemid 43816068)
12. Cook RJ, Sackett DL (1995) The number needed to treat: a clinically useful measure of treatment effect. BMJ 310:452-454
13. Coryell W (2009) Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. Bipolar Disord 11(Suppl 2):77-83
14. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R (2004) A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65:432-441
15. Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen HU (2008) ECNP consensus meeting. Bipolar depression. Nice, March (2007). Eur Neuropsychopharmacol 18:535-549
16. Gray G (2004) Concise guide to evidence-based psychiatry. American Psychiatric Publishing Inc, Washington, DC, pp 67-68
17. Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, Carlson BX, Marcus RN, Sanchez R, Aripiprazole Study Group (2007) Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 68:1480-1491 (Pubitemid 350073394)
18. Kraemer HC, Kupfer DJ (2006) Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 59:990-996 (Pubitemid 43849650)
19. Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, Kujawa M, Mahmoud R (2009) A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 11:827-839
20. Martinez-Aran A, Vieta E, Chengappa KN, Gershon S, Mullen J, Paulsson B (2008) Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. Bipolar Disord 10:566-579 (Pubitemid 352003825)
21. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME (2006) Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 163:217-224 (Pubitemid 44480840)
22. Prien RF, Caffey EM Jr, Klett CJ (1973) Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 28:337-341
23. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V (2010) Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 68:156-162
24. Richy F, Ethgen O, Bruyere O, Deceulaer F, et al. (2004) From sample size to effect-size: small study effect investigation (SSEi). The Internet Journal of Epidemiology 1
25. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B (2009) Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 166:476-488
26. Thase ME (2008) Selecting appropriate treatments for maintenance therapy for bipolar disorder. J Clin Psychiatry 69(5):28-35
27. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer DJ, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR (2004) Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 184:337-345
28. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, Baker RW, Chou JC, Bowden CL (2006) Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 163:247-256 (Pubitemid 44480844)
29. Vieta E, Berk M, Wang W, Colom F, Tohen M, Baldessarini RJ (2009) Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord 119:22-27
30. Vieta E, Cruz N, García-Campayo J, de Arce R, Manuel Crespo J, Vallès V, Pérez-Blanco J, Roca E, Manuel Olivares J, Moríñigo A, Fernández-Villamor R, Comes M (2008a) A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 11:445-452 (Pubitemid 351744814)
31. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M (2008b) Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 109:251-263
32. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B (2008). Quetiapine or lithium versus placebo for maintenance treatment of bipolar I disorder after stabilization on quetiapine. Presented at the 60th Institute on Psychiatric Services Congress, Chicago, IL, 2-5 October 2008
33. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Young AH, Alda M, Milev R, Vieta E, Calabrese JR, Berk M, Ha K, Kapczinski F (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 11:225-255